MA53270A - Diazabicyclooctanones en tant qu'inhibiteurs de bêta-lactamases à sérine - Google Patents

Diazabicyclooctanones en tant qu'inhibiteurs de bêta-lactamases à sérine

Info

Publication number
MA53270A
MA53270A MA053270A MA53270A MA53270A MA 53270 A MA53270 A MA 53270A MA 053270 A MA053270 A MA 053270A MA 53270 A MA53270 A MA 53270A MA 53270 A MA53270 A MA 53270A
Authority
MA
Morocco
Prior art keywords
diazabicyclooctanones
serin
beta
lactamase inhibitors
lactamase
Prior art date
Application number
MA053270A
Other languages
English (en)
Other versions
MA53270B1 (fr
Inventor
David Thomas Davies
Simon Leiris
Original Assignee
Antabio Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antabio Sas filed Critical Antabio Sas
Priority claimed from PCT/EP2019/071370 external-priority patent/WO2020030761A1/fr
Publication of MA53270A publication Critical patent/MA53270A/fr
Publication of MA53270B1 publication Critical patent/MA53270B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA53270A 2018-12-18 2019-08-08 Diazabicyclooctanones comme inhibiteurs de sérine beta-lactamases MA53270B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18213635.8A EP3670512A1 (fr) 2018-12-18 2018-12-18 Diazabicyclooctanones comme inhibiteurs de sérine beta-lactamases
PCT/EP2019/071370 WO2020030761A1 (fr) 2018-08-09 2019-08-08 Diazabicyclooctanones en tant qu'inhibiteurs de bêta-lactamases à sérine

Publications (2)

Publication Number Publication Date
MA53270A true MA53270A (fr) 2022-04-06
MA53270B1 MA53270B1 (fr) 2023-11-30

Family

ID=64745939

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53270A MA53270B1 (fr) 2018-12-18 2019-08-08 Diazabicyclooctanones comme inhibiteurs de sérine beta-lactamases

Country Status (4)

Country Link
EP (1) EP3670512A1 (fr)
EA (1) EA202190444A1 (fr)
MA (1) MA53270B1 (fr)
PT (1) PT3833665T (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2533826T3 (es) * 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
MX340533B (es) * 2011-08-30 2016-07-13 Wockhardt Ltd Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
GB2533136A (en) 2014-12-11 2016-06-15 Antabio Sas Compounds
CN107501265B (zh) * 2017-10-09 2019-05-28 台州职业技术学院 一种7-氧代-二氮杂二环[3,2,1]辛烷衍生化合物及其制备方法和应用

Also Published As

Publication number Publication date
PT3833665T (pt) 2023-10-19
EA202190444A1 (ru) 2021-06-18
MA53270B1 (fr) 2023-11-30
EP3670512A1 (fr) 2020-06-24

Similar Documents

Publication Publication Date Title
MA54546A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA54547A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
EP3843714A4 (fr) Inhibiteurs de cd73
MA51232A (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
EP3875460A4 (fr) Dérivé de pyrimidopyrazolone en tant qu'inhibiteur de wee1 et son utilisation
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
DK3687994T3 (da) Gadolinium-bærende pcta-baserede kontrastmidler
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
MA52413A (fr) Inhibiteurs de cd73
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA44725A (fr) Formulations d'un inhibiteur de lsd1
EP3464275A4 (fr) Composés inhibiteurs de l'egfr
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA46242A (fr) Composés inhibiteurs de bêta-lactamase
EP3697787A4 (fr) Composé hétérocyclique à utiliser en tant qu'inhibiteur de protéine kinase
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
EP3787635A4 (fr) Inhibiteurs de cd73
MA49879A (fr) Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca
EP4013496A4 (fr) Thrombosomes en tant qu'agent désactivateur d'antiagrégant plaquettaire
EP3953331A4 (fr) Pyrazolesulfonamides en tant qu'agents antitumoraux
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
MA53643A (fr) Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6
EP3822276A4 (fr) Composé hétérocyclique utilisé en tant qu'inhibiteur de trk
EP3781574A4 (fr) Spiroéthers macrocycliques utilisés en tant qu'inhibiteurs de mcl-1